Risk-reducing salpingo-oophorectomy is currently advocated for the reduction of both breast and ovarian cancer risk in BRCA1/2 carriers, but residual risk of peritoneal primary cancer remains a concern. A sequential series of women attending a single institution for ovarian risk management underwent either risk-reducing surgery or screening. A person-years at risk analysis was used to compare observed versus expected cancers. In total, 300 women underwent risk-reducing salpingo-oophorectomy, including 160 BRCA1/2 mutation carriers. Three occult ovarian cancers were detected at surgery. There have been 2400.4 years of follow-up and 15.79 expected cancers. No peritoneal cancers have occurred. Amongst 503 women controls with 3444.3 years of follow-up, 15.93 ovarian cancers were expected and 17 were found. There were six ovarian cancer-related deaths in the control group compared with one in the surgery group. Risk-reducing salpingo-oophorectomy in a single institution has so far avoided peritoneal cancer incidence.
Introduction
Ovarian cancer is the most common gynaecological cancer, affecting B1 in 70 of the general female population. Ovarian cancer generally presents late, and the overall 5-year survival for ovarian cancer is only 28%. However, if diagnosed at stages 1 -2, the prognosis is much improved with a 5-year survival of up to 84%. 1 Epithelial tumours account for over 90% of all ovarian cancers and the lifetime risk is estimated to be between 1 and 1.5% for the average woman. This risk increases with the number of affected relatives with ovarian cancer and the closeness of the relationship. The lifetime risk estimate for women with one first degree relative is 2 -5% and when there is more than one close relative affected, the risk increases to 10 -23%. 2 -4 Highly penetrant cancerpredisposing genes account for 8 -13% of all epithelial ovarian cancers in non-founder populations, 3 -6 but this increases to 23% in Norway, and is even higher in the Jewish population. 7 Those identified to date include BRCA1 and BRCA2, associated with breast and ovarian cancer, and the mismatch repair genes associated with Hereditary Non-Polyposis Colon Cancer (HNPCC). Germline mutations in these two classes of genes can confer an increased risk of ovarian cancer of up to 60 and 12%, respectively. 8 -10 In most instances, increased genetic risk is initially recognised from family history, and mutation screening may then become available. For women at increased risk, management options include ovarian screening and prophylactic surgery. 3 Demand for ovarian cancer screening has risen, yet there is no clear evidence of its effectiveness in groups at increased risk. 10 -14 Indeed, survival in screened individuals with BRCA1/2 mutations is little different to what might be expected without screening, although there may be a benefit in Lynch syndrome. 14 Despite the paucity of evidence of efficacy of ovarian screening, many reviews remain upbeat regarding the potential outcomes of surveillance. 15 In contrast, the efficacy of risk-reducing surgery is proven with a risk reduction of 79 -95%. 16 -18 However, there is still a concern regarding the risk of peritoneal primary malignancy 16 -19 in high-risk families. We have reviewed our experience at a single gynaecology centre offering riskreducing surgery. Women in the control group were those on annual screening with ovarian ultrasound and serum CA125. The protocol being used since 2000 is for screening women above 35 years of age. However, since 1990, some women were being screened from age 30 years. Follow-up was from first scan to time of most recent scan, cancer detection or death. Patients were treated according to preference and not randomised to surveillance or surgery. All ovarian cancers relevant to the individual's risk were confirmed from hospital records, death certificates or from the NWCIS.
Patients and methods

Results
(1) BSO group A total of 300 women have undergone risk-reducing surgery with 265 full hysterectomies and BSO, and 35 laparoscopic BSO surgical procedures. A total of 160 BRCA1/2 carriers have undergone surgery (104 BRCA1, 56 BRCA2). Three occult malignancies were discovered at the time of surgery. Two BRCA1 carriers had a stage 3 and a stage 1c cancer, and a BRCA2 carrier had a stage 1b cancer. The stage 3 cancer resulted in the death of the patient within 3 years. A fourth BRCA1 mutation carrier had disseminated abdominal malignancy from her original primary breast cancer.
There have been 2400.37 years of follow-up (range 0 -27 years; mean 8.17 years median 7.27) and 15.79 (95% confidence interval (CI) 8.3 -24.6) expected cancers. No peritoneal cancers have occurred. The maximum number of cancers that would be consistent at P ¼ 0.05, with observing zero among the surgical patients, is nine. A total of 14 women developed breast cancer in the follow-up period (68 mutation carriers had also undergone risk-reducing mastectomy).
Control group
There were 503 women who have not chosen risk-reducing BSO. A further 135 patients who eventually undertook riskreducing BSO contributed to the follow-up time up until their surgery (two had occult cancers at BSO). There were 3444.25 years follow-up (range 1 -17 years; mean 6.8 years; median 7.18, 94 women 410 years), 15.93 (95% CI 8.4 -24.75) cancers were expected and 19 were found (15 excluding two cancers detected on prevalence screen and two at risk-reducing BSO). A total of 180 women were from families with known BRCA1 or BRCA2 mutations (20 were at 50% risk of a mutation). A total of 104 BRCA1 mutation carriers had 655.41 years follow-up with 8.19 expected cancers and 56 BRCA2 carriers had 316.14 years follow-up with 1.58 expected cancers. Nine cancers occurred in BRCA1 mutation carriers, one in a BRCA2 carrier and two in carriers of HNPCC-related mismatch repair gene defects. These two women aged 32 and 34 years, with MSH2 mutations were detected at stage 1c at incident screens (endometrioid 2653 C4T (Q885X) mutation; and clear cell with a 942 þ 3 A4T splicing mutation). Furthermore, one patient with an earlier bilateral breast cancer who developed ovarian cancer in follow-up had a BRCA1 5313À12 G4A mutation, which could affect splicing. Two patients aged 32 and 73 years, a BRCA1 and a BRCA2 mutation carrier, developed occult stage 1 ovarian cancer detected at riskreducing surgery 6 and 10 months after normal ultrasound and CA125 screening (see above). All other cancers occurred between 46 and 68 years of age. Three cancers, including a borderline malignancy, occurred in individuals untested for BRCA1/2. The majority of screened individuals who did not develop ovarian cancer were also unscreened for BRCA1/2 (Table 1) . A total of 6 of the 17 women (19 including the two found at BSO) with ovarian cancer in the screened group have died, and five with stage 3 disease have relapsed after chemotherapy and have residual disease. It is likely, therefore, that 11 of 17 (65%) will eventually succumb to ovarian cancer compared with 1 of 15.8 (7%) of the expected cancers in the surgery group.
Peritoneal primary rates in women not having undergone BSO Of 245 ovarian cancers in BRCA1/2 mutation carriers on the database, only seven (3%) were designated as peritoneal primary malignancy.
Discussion
This report documents the medium term follow-up of 300 women at high-risk of ovarian cancer who have undergone risk-reducing surgery. This study has reinforced the efficacy of this surgery to reduce ovarian cancer risk. No cancers have occurred after surgery, whereas over 15 were expected, and the upper end of the 95% CI are still equivalent to an 81% reduction in risk. This is significantly better than the pooled data from 10 studies, which gave a 79% overall reduction. 16 Two peritoneal primaries were reported in a large combined series of 259 BRCA1/2 mutation carriers undertaking BSO, although 56 ovarian cancers occurred in 292 controls. 17 This was equivalent to a 96% reduction in risk. In a smaller study of 170 women, 98 chose risk-reducing salpingo-oophorectomy, and peritoneal cancer was diagnosed in one woman. 18 Amongst 72 women who chose surveillance in this study, ovarian cancer occurred in four, and peritoneal cancer in one; this was equivalent to a 75% reduction in risk. Although our report has fewer mutation carriers than the first of these reports from 2002, 17 it also includes women from families without proven mutations. Three of the expected cancers and six of those in the controls occurred in women not known to be BRCA1/2 mutation carriers. A larger combined study from the first two groups on 1079 mutation carriers found an 85% reduction in gynaecological malignancy for BRCA1 carriers. 18 Three peritoneal primary cancers occurred in a mean follow-up of 40 months amongst 325 women undertaking surgery. The potential accuracy of our risk prediction is shown by the control group, although the CIs were still wide. The cancers detected in BRCA1/2 carriers and in non-carriers were virtually identical to that predicted. The control group, although larger, contained a substantial group of women with lower overall predicted risk (Table 1) . This accounts for the 0.46% annual risk compared with the 0.66% risk predicted in the surgery group. Although we have not carried out a direct matching exercise of cases and controls, the accuracy of the predictions has been bourne out by our analysis.
The rate of occult malignancy is identical to that found in the two earlier reports in mutation carriers. 17, 19 A total of 3 of 160 (2%) had occult malignancy in our report compared with 6 of 259 (2.3%) in the larger report. 17 A higher rate of occult malignancy has been found if extra pathological examinations are carried out with seven occult malignancies discovered, four in the fallopian tube and three in the ovaries, amongst 76 cases. 20 Six of these were microscopic. It is arguable whether we would have detected more cancers with a more thorough protocol, but none of the patients without malignancy detected have gone on to develop signs of invasive disease. In contrast to the study by Rebbeck et al, 17 which used controls who were not necessarily undergoing surveillance, we have only used controls who were prospectively followed on an active annual surveillance programme. Despite this surveillance, women on an annual programme of CA125 and ovarian ultrasound will still present These women contributed time to the screening data, but eventually chose BSO before symptoms or abnormalities on screening. b Chose BSO surgery while on ovarian screening, but no abnormality on screening tests. c Borderline mucinous tumour. The higher rates of expected cancers in the BSO group reflect the longer follow-up of BRCA1/2 mutation carriers in the surgical group.
Risk-reducing surgery for ovarian cancer DGR Evans et al predominantly with late-stage disease (Table 2 ). This is shown from our own data and a combined analysis from five centres of 63 ovarian tumours in a screening programme with 10-year survival of only 36%. 21 As such, 11 ovarian cancer deaths may have been expected out of the 15.79 cancers expected in the surgical group, with one actually dying from a cancer detected at surgery. As such, close to 13 ovarian cancers and 10 ovarian cancer deaths will most likely have already been prevented in the surgery group. With further follow-up, it is likely that this benefit would be greatly increased given the absence of cancers found after surgery. We are not able to comment on any benefit from the prevention of breast cancer or breast cancer death due to the absence of direct matching of cases in this study. It is nonetheless likely that breast cancers will be prevented in women undergoing early BSO with around a 50% reduction in risk. 17 The debate as to the frequency of peritoneal malignancy after surgery still pertains. In 324 women who underwent prophylactic BSO in an ovarian cancer family registry, primary peritoneal carcinoma histologically indistinguishable from primary ovarian adenocarcinoma developed in six of them. 20 Such malignancy could reflect undetected occult disease removed at surgery or the development of disease in ovarian epithelial tissue lodged during embryological development. In particular, the high rate of tubal malignancy and occult disease in reports 22 emphasises the need to remove the fallopian tube in its entirety. Alternatively, epithelial ovarian cells on the surface of the ovaries could be displaced into the peritoneum at the time of surgery. We are aware of one peritoneal cancer occurring in a 56-year-old BRCA1 carrier 4 years after BSO at another centre in our region. An increased risk in the peritoneum is suggested by the apparently higher rates of peritoneal primary disease in mutation carriers after surgery. Only 6 of 244 (2.4%) of ovarian cancers were designated as of peritoneal origin in our mutation carriers, excluding the case found after surgery from another centre. It is possible that some stage 3 or 4 disease is wrongly labelled as starting in the ovaries, nonetheless, the risk reduction of 96% in the paper by Rebbeck et al 17 suggests that o10% of the ovarian type risk resides in the peritoneum. Absolute risks of peritoneal cancer in follow-up are still o1% in BSO series. 17, 19 The result that no peritoneal cancers were found during follow-up after surgery, may be because of the relatively small number of patients or the length of followup. Nonetheless, our data support the careful approach to ovarian risk-reducing surgery carried out by this and many other centres, although direct comparisons of techniques in large numbers of women would be required for proof of benefit. Only one breast cancer death per group was attributable to a breast cancer occurring after commencement of follow-up in either BSO or screening group.
Risk-reducing surgery for ovarian cancer DGR Evans et al
